Named-patient

From WikiCover

Named-patient distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In most countries, this program provides for full cost recovery of providing late-stage investigational drugs that are either pending regulatory approval or are in late-stage clinical trials that are intended to lead to formal regulatory approval.

For example, on August 13, 2007, Genta announced the launch and initial sales of Genasense on a named patient/compassionate use basis outside the United States.